Male study dosing
1–12 mg once weeklyRange studied in the Phase 2 trial
RESEARCH USE ONLY · 18+
You must be of legal age in your province and a qualified research professional. All products are for in vitro laboratory research only — not for human or animal consumption.
By entering you confirm you are 18+ and accessing this site in a qualified research capacity. Products are not intended for personal, therapeutic, or clinical use.
You must be 18 years of age or older to enter MGMT Research.
MGMT RESEARCH

Retatrutide · Triple-receptor agonist
A 10 mg lyophilized research compound for investigating GLP-1, GIP, and glucagon signaling, appetite regulation, and metabolic pathways.
COA pending. Independent testing will be performed by SideChain Analytics in Mississauga, Ontario.
Buy 2–5 eligible compound vials: receive one free 3 mL BAC Water. Buy 6 or more: receive one free BAC Water per eligible compound vial. Mix available compounds. AFTERBURN and RETROD Duo are excluded.
View BAC WaterTax-inclusive CAD pricing. E-transfer accepted · Credit cards coming soon.
Mix Easy · Open the calculator ↗Read RETROD | The benefits no one talks about →
Read RETROD | How long can I take it? →
Range studied in the Phase 2 trial
Range studied in the Phase 2 trial
Clinical study schedule
Investigational administration
Human pharmacokinetic research
No validated PCT protocol
Phase 2 trial arms: 1, 4, 8, and 12 mg once weekly. These study doses were not separate male/female recommendations or directions for using MGMT Research vials. Published study ↗
RETROD is our name for Retatrutide (LY3437943), a synthetic peptide investigated for its combined activity at the GLP-1, GIP, and glucagon receptors. These pathways are involved in appetite, glucose regulation, and energy metabolism.
Your selected vial contains 10 mg of labeled lyophilized compound. This is the total vial amount, not a dose or a solution concentration. RETROD is sourced through a Canadian supplier partner and is not filled in-house by MGMT Research.
COA results are pending. Independent testing will be performed by SideChain Analytics in Mississauga, Ontario; verified purity and net-content figures will be published when available.
Retatrutide is studied for potential effects on body weight and metabolic health. These are research findings, not promised outcomes from this product.
Follow batch-specific supplier instructions and your laboratory’s validated storage and reconstitution procedures. A prepared solution’s shelf life has not been established for this product.
Orders received before 12 PM EST ship the same business day.
COA pending. Purity and net-content results will be published when the batch-specific report is available.
Select your compound, vial amount, diluent volume, and sample amount. Our calculator converts your inputs into a concentration, volume, and U-100 syringe marking.
Enter an example amount to calculate its volume.
0.2 mL of solution per sample
2 mg ÷ 10 mg/mL = 0.2 mL
Concentration = vial amount ÷ solution volume. Sample volume = sample amount ÷ concentration. U-100 scale units = volume in mL × 100; these are volume markings, not units of compound potency.
This example assumes the final solution volume equals the diluent volume entered, and that the compound dissolves completely. It does not establish solubility, compatibility, stability, or an administration dose.
Decimal measurements are mathematical results and may fall between markings. Full samples are rounded down; they do not account for handling losses.
The calculator checks concentration mathematics. It does not select a treatment dose or establish compatibility, sterility, or stability. SEMARO is temporarily unavailable and is omitted from this selector. BAC Water is the diluent, not a peptide.
In the Phase 2 study, gastrointestinal adverse events were most common and increased with dose. Heart-rate increases were also observed. Longer-term safety remains under investigation.
Retatrutide remains investigational, with no regulatory approval. Research-grade MGMT Research vials are not clinical-trial medication.
Your selected RETROD vial is labeled 10 mg. There is no approved male or female dosing regimen for this research product.
Adults were assigned 1, 4, 8, or 12 mg once weekly for 48 weeks under a controlled protocol. These are study details, not self-use instructions.
TRIUMPH-4 · 12 mg target-dose arm
Lilly reported once-weekly dosing with four-week escalation steps. Expressed as treatment weeks, the planned sequence was:
The trial also included a 9 mg target-dose arm. Participants followed a controlled study protocol with clinical oversight; this is research information, not a suggested RETROD self-use or maintenance plan.
Source: Lilly’s TRIUMPH-4 study summary ↗Explore the research context, vial quantities and concentration calculations in our beginner’s guide.
Read the full RETROD guide →Laboratory sample amounts and preparation procedures should come from your validated protocol. Enter those amounts into Mix Easy to check the volume calculation.
Open Mix Easy ↗Read the original trial ↗